Skip to Content

Generic Oxtellar XR Availability

Oxtellar XR is a brand name of oxcarbazepine, approved by the FDA in the following formulation(s):

OXTELLAR XR (oxcarbazepine - tablet, extended release;oral)

  • Manufacturer: SUPERNUS PHARMS
    Approval date: October 19, 2012
    Strength(s): [RLD], [RLD], [RLD]

Has a generic version of Oxtellar XR been approved?

No. There is currently no therapeutically equivalent version of Oxtellar XR available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oxtellar XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Modified-release preparations containing oxcarbazepine and derivatives thereof
    Patent 7,722,898
    Issued: May 25, 2010
    Inventor(s): Bhatt; Padmanabh P. & Kidane; Argaw & Edwards; Kevin
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Patent expiration dates:
    • April 13, 2027
      ✓ 
      Drug product
  • Method of treating seizures using modified release formulations of oxcarbazepine
    Patent 7,910,131
    Issued: March 22, 2011
    Inventor(s): Bhatt; Padmanabh P. & Kidane; Argaw & Edwards; Kevin
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Patent expiration dates:
    • April 13, 2027
      ✓ 
      Patent use: ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
  • Modified release preparations containing oxcarbazepine and derivatives thereof
    Patent 8,617,600
    Issued: December 31, 2013
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Patent expiration dates:
    • April 13, 2027
      ✓ 
      Drug product
  • Modified release preparations containing oxcarbazepine and derivatives thereof
    Patent 8,821,930
    Issued: September 2, 2014
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Patent expiration dates:
    • April 13, 2027
      ✓ 
      Drug product
  • Modified release preparations containing oxcarbazepine and derivatives thereof
    Patent 9,119,791
    Issued: September 1, 2015
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Patent expiration dates:
    • April 13, 2027
      ✓ 
      Patent use: ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
  • Modified release preparations containing oxcarbazepine and derivatives thereof
    Patent 9,351,975
    Issued: May 31, 2016
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Patent expiration dates:
    • April 13, 2027
      ✓ 
      Drug product
  • Modified release preparations containing oxcarbazepine and derivatives thereof
    Patent 9,370,525
    Issued: June 21, 2016
    Assignee(s): Supernus Pharmaceuticals, Inc.
    Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Patent expiration dates:
    • April 13, 2027
      ✓ 
      Drug product
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide